NCT07207291View on ClinicalTrials.gov

Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

August 22, 2025

Primary Completion Date

March 19, 2026

Study Completion Date

March 19, 2026

Conditions
Bacterial InfectionsUrinary Tract InfectionsIntra-Abdominal InfectionsRespiratory Tract Infections
Interventions
DRUG

JKN2501

Administration: Intravenous (IV) infusion.

DRUG

Placebo

0.9% Sodium Chloride Injection as Placebo. Administration: Intravenous (IV) infusion.

Trial Locations (1)

410035

RECRUITING

The Third hospital of Changsha, Changsha

All Listed Sponsors
lead

Joincare Pharmaceutical Group Industry Co., Ltd

INDUSTRY